The udi is unknown because the part number and lot number were not provided.The device was not returned for evaluation.A review of the lot history record of the reported lot could not be conducted because the part and lot number were not provided.The reported patient effects of stenosis and pain are listed in the supera peripheral stent system instructions for use as potential adverse effects of peripheral percutaneous intervention.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.However, the treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was performed to treat a lesion in the heavily calcified common femoral artery.An unspecified supera self-expanding stent was implanted on (b)(6) 2021.On (b)(6) 2021, the stent was noted to have narrowed, and the patient experienced claudication with the restenosis.The stent was surgically removed without issue.The patient is doing well.There were no adverse patient sequelae and no clinically significant delay in the procedure.No additional information was provided.
|